Welcome to the Cologne Conference on Lung Cancer
Due to the challenges posed by the COVID-19 pandemic, the Cologne Conference on Lung Cancer could not take place in recent years. This decision was made to ensure the safety and well-being of our attendees, as well as to maintain the high standards of our conference.
The pace at which new therapies for lung cancer are being developed is breathtaking. Thus, we are looking forward to welcome you again to this much-awaited congress, where we will once again gather to share the latest advancements and research in lung cancer.
We are expecting a highly interactive meeting sparked by the panel of internationally renowned speakers, who will discuss their latest research developments.
We would like to thank all guest speakers for their active participation and engagement. We are looking forward to welcoming you and wish all participants who will travel to Cologne a pleasant journey.
Our chairs
Prof. Caroline Dive / credit: Cancer Research UK
Chairwoman: Prof. Caroline Dive
We are pleased to announce that Prof. Caroline Dive is the Chairwoman for our 3rd CCLC. Prof Dive is internationally renowned for advancing circulating biomarker research in lung cancer. As the Interim Director of the Cancer Research UK Manchester Institute and Director of the CRUK National Biomarker Centre, she has revolutionized the field of biomarker research and early clinical trial activities.
Prof. Dive’s contributions to cancer research have been widely recognized with numerous awards and honors, and she continues to be a driving force in the pursuit of innovative cancer treatments. We are honored to have her as Chairwoman and that she will share her expertise and insights at the 3rd Cologne Conference on Lung Cancer in 2025.
Founders of CCLC
Further we are delighted to announce again Prof. Jürgen Wolf, Prof. Reinhard Büttner and Prof. Roman Thomas as founders of the CCLC. Lately, they were awarded the prestigious German Cancer Aid Prize (2023) for their collaborative efforts in advancing lung cancer research and therapy and implementing personalized lung cancer care into clinical routine.
Prof. Jürgen Wolf / credit: BMS; Johannes Jost
Prof. Jürgen Wolf
Prof. Jürgen Wolf is the Medical Director of the Center for Integrated Oncology (CIO) at the University Hospital Cologne and co-founder of the national Network Genomic Medicine. He has led innovative clinical trials and contributed to the development of targeted therapies. His work focuses on translating research findings into effective treatments for patients. Prof. Wolf’s expertise and dedication have significantly advanced lung cancer care.
Prof. Reinhard Büttner / credit: Michael Wodak; MedizinFotoKöln
Prof. Reinhard Büttner
Prof. Reinhard Büttner leads the Institute of Pathology and Pathological Anatomy at the University Hospital Cologne, where his research focuses on the molecular mechanisms of cancer, particularly in discovering biomarkers. Prof. Büttner’s work has been instrumental in advancing personalized medicine for cancer patients.
(autorisiert von) Prof. Roman Thomas
Prof. Roman Thomas
Prof. Roman Thomas is the head of the Department of Translational Genomics at the University of Cologne and has made significant contributions to understanding the genetic alterations driving lung cancer. His research focuses on identifying novel therapeutic targets and developing personalized treatment approaches. Prof. Thomas’s work has earned him international recognition and numerous awards.
New therapies for lung cancer are being developed
The pace at which new therapies for lung cancer are being developed is breathtaking. Novel strategies include newer generations of inhibitors targeting mutant kinases as well as more refined modes of applications of immunotherapy.
